8.4 Lead, Mercury, Arsenic, Iron Toxicity, and Chelation Protocols

Heavy metals (lead, mercury, arsenic) and transition metals (iron) represent unique challenges in clinical toxicology. Unlike organic toxins that are metabolized and cleared over hours to days, heavy metals persist indefinitely in the body, binding to functional sulfhydryl groups, disrupting essential cellular cofactors, mimicking physiological divalent cations (Ca²⁺, Zn²⁺), and catalyzing destructive free radical chain reactions. Successful clinical management requires an understanding of chemical speciation, organ-specific sequestration, mandatory chelator administration sequences, and advanced gut decontamination.

---

Lead Toxicity (Plumbism): Pathophysiology and Chelation Sequencing

Lead (Pb²⁺) is a ubiquitous environmental and occupational toxin absorbed via inhalation or ingestion. Following absorption, lead distributes into blood (erythrocytes), soft tissues (brain, kidneys, liver), and ultimately incorporates into the crystalline hydroxyapatite matrix of bone, where its half-life spans 20 to 30 years.

Biochemical Mechanisms of Lead Toxicity

1. Inhibition of Heme Biosynthesis: Lead binds high-affinity sulfhydryl (-SH) groups on critical zinc-dependent enzymes in the heme synthetic pathway:
   • δ-Aminolevulinic Acid Dehydratase (ALAD): Inhibition causes systemic accumulation of δ-aminolevulinic acid (ALA). ALA shares structural homology with GABA, producing central neurotoxicity.
   • Ferrochelatase: Inhibits the insertion of ferrous iron (Fe²⁺) into protoporphyrin IX. Zinc is incorporated in place of iron, leading to high circulating concentrations of zinc protoporphyrin (ZPP) and free erythrocyte protoporphyrin (FEP).
2. Pyrimidine-5'-Nucleotidase Inhibition: Lead inactivates this enzyme, preventing the normal enzymatic degradation of ribosomal RNA in reticulocytes. Undegraded polyribosomes precipitate as dense basophilic aggregates visible on peripheral blood smear as basophilic stippling.

Clinical Manifestations: Adults vs. Children

Pediatric Chelation Guidelines and The 4-Hour BAL Rule

Chelation therapy forms water-soluble metal-chelator ring complexes that are excreted renally or biliarially. Management is stratified by Whole Blood Lead Level (BLL):

BLL 45–69 mcg/dL (Asymptomatic):   Oral Succimer (DMSA) Outpatient Regimen (19 Days)
BLL >= 70 mcg/dL or Encephalopathy: Dual Inpatient Chelation: BAL (IM) FIRST ──(Wait 4 Hours)──> CaNa2-EDTA (IV)

• Blood Lead Level 45 to 69 mcg/dL (Asymptomatic Pediatric Patient):
  • Treat with oral Succimer (DMSA, dimercaptosuccinic acid) at 10 mg/kg (or 350 mg/m²) orally three times daily for 5 days, then twice daily for 14 days (total 19-day course).
  • DMSA is a water-soluble analog of dimercaprol that chelates lead without redistributing it into brain tissue and can be administered safely in an outpatient setting.
• Blood Lead Level ≥ 70 mcg/dL OR Any Patient with Acute Encephalopathy:
  • Requires emergent hospital admission and dual parenteral chelation with Dimercaprol (BAL, British Anti-Lewisite) PLUS Calcium Disodium EDTA (CaNa₂-EDTA).

CRITICAL CHELATION SAFETY MANDATE (THE 4-HOUR BAL RULE): In severe lead toxicity, Dimercaprol (BAL) MUST ALWAYS BE ADMINISTERED AT LEAST 4 HOURS BEFORE the first dose of Calcium Disodium EDTA (CaNa₂-EDTA). Pathophysiological Rationale: CaNa₂-EDTA is a hydrophilic extracellular chelator. If administered alone, it rapidly mobilizes lead from osseous and soft-tissue stores into the bloodstream. This surge of mobilized free lead redistributes across the blood-brain barrier into cerebral parenchyma, acutely worsening cerebral edema and triggering fatal brain herniation! BAL is lipophilic, crosses the blood-brain barrier, and chelates central and intracellular lead first. Once BAL is on board, CaNa₂-EDTA is co-administered to chelate circulating lead for rapid renal elimination.

FATAL CONTRAINDICATION (DISODIUM EDTA BLACK BOX WARNING): NEVER administer Disodium EDTA (Na₂-EDTA) for lead poisoning. Na₂-EDTA is not saturated with calcium; it rapidly binds circulating ionized calcium, producing catastrophic, fatal hypocalcemia and cardiac arrest. Only Calcium Disodium EDTA (CaNa₂-EDTA) must be dispensed.

• Peanut Oil Formulation: Dimercaprol (BAL) is formulated in peanut oil for deep intramuscular injection; it is strictly contraindicated or requires extreme caution in patients with peanut allergies.

---

Mercury Toxicity: Speciation Dictates Clinical Pathology

Mercury exists in three distinct chemical forms, each displaying radically different pharmacokinetic distribution and clinical pathology.

1. Elemental Mercury (Hg⁰, Metallic Mercury)

• Ingestion: Swallowing liquid metallic mercury (e.g., from broken clinical thermometers or sphygmomanometers) has virtually zero gastrointestinal absorption (<0.01%). The metal passes harmlessly through the gastrointestinal tract and is eliminated in the stool; chelation is unnecessary.
• Inhalation of Vapor: Inhaling heated elemental mercury vapor results in >80% alveolar absorption. Acute vapor inhalation triggers hemorrhagic chemical pneumonitis, non-cardiogenic pulmonary edema, and ARDS. Chronic vapor exposure crosses the blood-brain barrier, yielding the classic neuropsychiatric triad:
  1. Erethism Mercurialis: Marked personality alterations, extreme timidity, anxiety, emotional lability, insomnia, and memory loss.
  2. Intentional Tremors: Coarse, irregular tremors affecting the fingers, tongue, and eyelids ('the mad hatter's shakes').
  3. Gingivostomatitis: Excessive salivation (ptyalism), metallic taste, swollen gums, and tooth loss.

2. Inorganic Mercury Salts (Mercuric Chloride, Hg²⁺; Mercurous Chloride, Hg₂²⁺)

• Ingested inorganic salts are highly corrosive to biological membranes. Ingestion produces immediate, severe corrosive gastroenteritis, grayish mucosal sloughing, hematochezia, and third-spacing shock.
• Following absorption, mercuric ions concentrate heavily in renal proximal tubules, producing severe acute tubular necrosis, oliguria, and anuric renal failure.

3. Organic Mercury (Methylmercury, Ethylmercury, Dimethylmercury)

• Bioaccumulation: Methylmercury accumulates up aquatic trophic webs into apex predatory fish (shark, swordfish, king mackerel, tilefish), historically producing Minamata disease in Japan.
• Target Organ Toxicity: Methylmercury binds L-cysteine, forming a complex that mimics methionine and crosses the blood-brain barrier via neutral amino acid transporters. Toxicity develops after a characteristic delayed latency period of weeks to months:
  • Concentric visual field constriction ('tunnel vision') and cortical blindness.
  • Cerebellar ataxia, dysmetria, and dysarthria.
  • Profound Teratogenicity: Readily crosses the placenta; fetuses display severe microcephaly, cerebral palsy, and mental deficiency despite maternal symptom-free states.
• Dimethylmercury Hazard: Liquid dimethylmercury rapidly permeates disposable latex or nitrile gloves within seconds, absorbing through the skin to cause delayed, fatal neurodegenerative decline.

Mercury Chelation Principles

• Succimer (DMSA) is the oral chelator of choice for both elemental vapor and inorganic mercury toxicity.
• CRITICAL CONTRAINDICATION: BAL is strictly contraindicated in organic (methylmercury) toxicity. Dimercaprol forms lipophilic complexes with methylmercury that cross the blood-brain barrier, dramatically increasing brain mercury concentrations and accelerating neurotoxicity.

---

Arsenic Toxicity: Cellular Paralyzer and Carcinogen

Arsenic is an ancient metalloid toxin present in contaminated well water, agricultural pesticides, industrial smelting, and traditional medicinal remedies.

Biochemical Mechanisms of Toxicity

• Trivalent Arsenic (Arsenite, As³⁺): Binds vicinal sulfhydryl groups, potently inhibiting the pyruvate dehydrogenase (PDH) complex by inactivating the dihydrolipoyl transacetylase cofactor. Paralyzes the Krebs cycle, halting pyruvate-to-acetyl-CoA conversion and aerobic ATP synthesis.
• Pentavalent Arsenic (Arsenate, As⁵⁺): Competitively mimics inorganic phosphate, uncoupling mitochondrial oxidative phosphorylation through spontaneous 'arsenolysis' of ADP.

Clinical Manifestations: Acute vs. Chronic Poisoning

Diagnostic and Chelation Protocols

• 24-Hour Urine Collection: The gold standard diagnostic test is a 24-hour urinary arsenic determination. Dietary Seafood Restriction: Patients must strictly abstain from seafood and shellfish for at least 48 hours prior to urine collection. Marine organisms contain non-toxic organic arsenic species (arsenobetaine and arsenocholine, 'fish arsenic') that are cleared renally and will produce massive, false-positive elevations on total urinary arsenic assays.
• Chelation: Acute severe poisoning is managed with intramuscular Dimercaprol (BAL), followed by transition to oral Succimer (DMSA) once gastrointestinal function stabilizes.

---

Iron Toxicity: Kinetic Staging and Deferoxamine Protocols

Iron is an essential transition metal present in daily multivitamin tablets, prenatal supplements, and therapeutic hematinics. Acute pediatric iron ingestions remain a major cause of fatal accidental home poisonings.

Elemental Iron Calculations

Iron toxicity is determined strictly by the amount of elemental iron ingested per kilogram of body weight, NOT the total weight of the iron salt. Calculating elemental iron is a mandatory poison center competency:

$\text{Total Ingested Elemental Iron (mg)} = \text{Number of Tablets} \times \text{Salt Strength (mg)} \times \%\text{ Elemental Iron}$

$\text{Dose Ingested (mg/kg)} = \frac{\text{Total Ingested Elemental Iron (mg)}}{\text{Patient Body Weight (kg)}}$

Toxic Dose Thresholds (Elemental Iron)

• < 20 mg/kg: Non-toxic; produces mild gastrointestinal irritation (nausea, self-limited vomiting).
• 20 to 60 mg/kg: Mild to moderate toxicity; significant vomiting, diarrhea, abdominal pain, potential systemic toxicity.
• > 60 mg/kg: Severe, potentially lethal toxicity; high risk of circulatory collapse, hepatic necrosis, and mortality.

The Five Clinical Stages of Iron Poisoning

1. Stage 1: Acute Gastrointestinal Phase (0.5 to 6 hours)
   • Iron exerts direct caustic corrosive action on gastric and intestinal mucosa.
   • Nausea, vomiting, abdominal pain, hematemesis, and melena.
   • Poison Center Golden Rule: If a patient remains completely asymptomatic and free of vomiting for 6 full hours post-ingestion, significant systemic iron poisoning is very unlikely.
2. Stage 2: Latent / Quiescent Phase (6 to 24 hours)
   • Characterized by the 'deceptive calm'. Gastrointestinal distress appears to resolve as free iron is cleared from the gut lumen and absorbed into tissues.
   • Subclinical cellular injury, worsening high anion gap metabolic acidosis, and cellular hypoperfusion progress silently.
3. Stage 3: Shock and Systemic Metabolic Toxicity (6 to 72 hours)
   • Circulating iron overwhelms serum transferrin binding capacity. Free circulating ferric ions (Fe³⁺) enter tissues, uncouple mitochondrial oxidative phosphorylation, and catalyze the Fenton reaction to generate massive amounts of destructive hydroxyl free radicals.
   • Severe high anion gap metabolic acidosis, profound lactic acidosis, cardiogenic shock, peripheral vasodilation, third-spacing, coagulopathy, and acute renal tubular necrosis.
4. Stage 4: Hepatic Failure (12 to 96 hours)
   • Iron delivered via portal blood accumulates directly in hepatocytes, producing periportal (Zone 1) hepatic necrosis.
   • Massive transaminitis, jaundice, coagulopathy, hypoglycemia, and acute hepatic failure.
5. Stage 5: Delayed Gastrointestinal Cicatrization (2 to 8 weeks)
   • Fibrotic healing of early mucosal corrosive ulcerations produces pyloric stenosis, gastric outlet obstruction, or small bowel strictures requiring surgical revision.

Decontamination and Deferoxamine Chelation Protocols

Decontamination:   Activated Charcoal DOES NOT BIND Iron (Contraindicated)
Radiography:       Abdominal X-ray (KUB) Identifies Radiopaque Pill Concretions
Whole Bowel Irr:   PEG-ELS at 1–2 L/h (Adults) or 25–40 mL/kg/h (Peds) via NG Tube
Specific Antidote: Deferoxamine (Desferal) IV Infusion at 15 mg/kg/h (Binds Fe3+ ──> Vin Rosé Urine)

• Activated Charcoal is Ineffective: Activated charcoal does NOT bind iron or other inorganic metals. It should never be administered for isolated iron ingestions.
• Abdominal Radiography (KUB): Iron tablets are radiopaque. An abdominal X-ray should be performed immediately to confirm ingestion, assess pill burden, and identify coalesced pharmacobezoars.
• Whole Bowel Irrigation (WBI): Indicated for substantial ingestions with visible radiopaque pills on radiography. Infuse Polyethylene Glycol-Electrolyte Solution (PEG-ELS, GoLYTELY) via nasogastric tube at 1 to 2 L/hour in adults (25 to 40 mL/kg/hour in children) until the rectal effluent is completely clear and repeat abdominal X-ray confirms complete pill evacuation.
• Deferoxamine (Desferal) Chelation:
  • Deferoxamine is a specific hexadentate chelator produced by Streptomyces pilosus. It binds ferric iron (Fe³⁺) in a 1:1 molar ratio to form ferrioxamine, a water-soluble chelate excreted by the kidneys.
  • Indications: Serum iron level > 500 mcg/dL, or significant systemic manifestations of toxicity (shock, lethargy, refractory metabolic acidosis, severe gastrointestinal hemorrhage).
  • Route & Dosing: Administer as a continuous intravenous infusion at 15 mg/kg/hour (higher rates have been used in massive overdoses only with medical toxicologist direction, because hypotension and pulmonary toxicity increase with rate and duration). Caution: Rapid IV bolus administration triggers massive histamine release, resulting in profound flushing, urticaria, and severe hypotension.
  • Monitoring Endpoints: Ferrioxamine excretion classically imparts a reddish-orange or salmon-pink discoloration to urine ('vin rosé' urine). However, the absence of vin rosé urine does NOT rule out toxicity. Chelation is discontinued when systemic symptoms resolve, the anion gap normalizes, the serum iron level drops below 350 mcg/dL, and the urine clears.
  • Complications: Prolonged deferoxamine infusions (> 24 hours) significantly increase the risk of pulmonary capillary injury leading to Acute Respiratory Distress Syndrome (ARDS). Deferoxamine also acts as an exogenous siderophore for Yersinia enterocolitica, dramatically increasing the risk of life-threatening Yersinia septicemia.

---

Heavy Metal and Chelator Quick Reference Guide